Terveystalo (HLSE:TTALO) Swings to Profit, Undervalued Status Reinforces Bullish Narratives

Terveystalo Oyj (HLSE:TTALO) has swung back to profitability, marking a notable turnaround after experiencing a 16.6% annual decline in earnings over the prior five years. Margins are now on firmer ground, while analysts expect EPS to grow 9.24% annually. This pace is slower than the Finnish market’s anticipated 16.2% profit growth rate but still represents a solid improvement for shareholders.

See our full analysis for Terveystalo Oyj.

Next up, we will see how these results compare to the leading narratives around Terveystalo and whether the latest performance confirms or challenges those views.

See what the community is saying about Terveystalo Oyj

Margins on the Mend: Profit Margin Now 6.8% and Forecast to Reach 9.3%

• Profit margin stands at 6.8% today, with analysts forecasting an increase to 9.3% within three years. This strengthens the company’s position to absorb cost volatility.
• According to the analysts' consensus view, this steady expansion is supported by ongoing investments in digital health technology and operational efficiencies, which are expected to reduce costs while improving net margins.
  • Consensus highlights that higher-margin service mixes, digital channel growth, and strategic M&A are all expected to drive sustainable gains.
  • However, risks around labor cost inflation and slower-than-expected digital ramp-up could prevent margins from reaching these targets.
• The potential for margin enhancements is closely tied to successful execution on digital transformation and efficiency programs. Analysts describe this as setting the stage for sustainable revenue growth and positive margin impact.
  • Nevertheless, the company’s heavy reliance on the Finnish market may expose it to regulatory and demand headwinds that could put these improvements at risk.

📊 Read the full Terveystalo Oyj Consensus Narrative.

Trading at a 12.9x P/E: Well Below Sector and DCF Fair Value

• Terveystalo’s price-to-earnings ratio is 12.9x, nearly half the Finnish healthcare peer average (30.6x) and below the European industry average (18.6x). It is also trading significantly under the DCF fair value estimate of €27.65.
• Based on the analysts' consensus view, this low P/E and large discount to both sector and DCF fair value position the company as a relative value play, especially if results continue to improve and risks around financial resilience are managed.
  • Bulls see room for multiple expansion if revenue momentum and margin growth materialize as projected, and the current share price of €9.14 recovers toward the sector’s higher multiples.
  • Analysts do caution that slower-than-market profit growth and questions around the company’s financial strength could keep the discount in place if trends do not improve.

Dividend Sustainability in Focus as Financial Strength Lags

• Risks flagged in the data note the company is not in a strong financial position and its dividend is considered potentially unsustainable. This complicates the bull case for reliable cash returns.
• Per the analysts' consensus view, while value investors may be attracted by the company’s multiple discounts and profit turnaround, concerns over financial strength and dividend durability could weigh on market sentiment if not addressed in future results.
  • Critics highlight that heavy reliance on the Finnish market and softness in recurring occupational health demand may heighten vulnerability to contract losses and cost headwinds.
  • Consensus underscores the importance of watching for further improvements in free cash flow and financial health metrics as key signals that would support a more sustainable payout.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Terveystalo Oyj on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have a unique angle on the figures? Share your perspective and craft a custom narrative in just a few minutes, then Do it your way.

A great starting point for your Terveystalo Oyj research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.

See What Else Is Out There

Terveystalo Oyj’s modest financial health and potential concerns around dividend sustainability could make consistent cash returns uncertain for investors.

If you’re seeking more reliable payout prospects, check out these 1979 dividend stocks with yields > 3% where you’ll find alternatives offering higher yields and stronger dividend track records.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com